ProQR Therapeutics (PRQR) Registration Filing summary

Company overview and business model

• Focuses on developing transformative RNA therapies using proprietary Axiomer RNA-editing platform targeting diseases with high unmet medical need.

• Pipeline includes programs for cholestatic diseases, cardiovascular diseases, rare neurodevelopmental disorders, and metabolic diseases, with initial clinical trials expected in late 2024/early 2025.

• Strategic collaborations include a global licensing and research partnership with Eli Lilly, expanded to cover up to 15 targets.

• Additional platform technology, Trident, targets suppression of nonsense mutations in genetic diseases.

• Operates as a Dutch public company with headquarters in Leiden and a U.S. office in Cambridge, MA.

Financial performance and metrics

• As of June 30, 2024, cash and cash equivalents were €78.97 million, with an as-adjusted figure of €143.99 million post-offering.

• Shareholders' equity as of June 30, 2024, was €32.85 million, increasing to €97.87 million as adjusted for the offering.

• Historical gross proceeds raised total €435 million from public offerings and private placements.

• Outstanding debt as of June 30, 2024, was €19.19 million.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended primarily for research and clinical development, expansion of R&D programs, working capital, capital expenditures, and general corporate purposes.

• Management retains broad discretion over allocation; proceeds may also be used for strategic acquisitions or business development.

• Pending use, proceeds may be invested in interest-bearing securities or U.S. government instruments.